CU20230025A7 - Formulación para la inmunización de cerdos por la vía oral - Google Patents

Formulación para la inmunización de cerdos por la vía oral

Info

Publication number
CU20230025A7
CU20230025A7 CU2023000025A CU20230025A CU20230025A7 CU 20230025 A7 CU20230025 A7 CU 20230025A7 CU 2023000025 A CU2023000025 A CU 2023000025A CU 20230025 A CU20230025 A CU 20230025A CU 20230025 A7 CU20230025 A7 CU 20230025A7
Authority
CU
Cuba
Prior art keywords
pigs
formulation
immunization
adjuvant
oral route
Prior art date
Application number
CU2023000025A
Other languages
English (en)
Inventor
Cano Carlos Antonio Duarte
Garcia Mario Pablo Estrada
García Mara Laura Hernandez
Gonzalez Thailin Lao
Orta Mary Karla Méndez
Pérez Danny Pérez
Mallon Alina Rodriguez
Moltó María Pilar Rodríguez
González Talía Caridad Sardina
Puga Yusmel Sordo
Pedroso Marisela Fátima Suarez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2023000025A priority Critical patent/CU20230025A7/es
Priority to KR1020257041572A priority patent/KR20260012737A/ko
Priority to EP24739076.8A priority patent/EP4714463A1/en
Priority to CN202480045895.2A priority patent/CN121463957A/zh
Priority to PCT/CU2024/050003 priority patent/WO2024235366A1/es
Publication of CU20230025A7 publication Critical patent/CU20230025A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/187—Hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>Formulación inmunogénica por via oral que comprende: i) una o varias proteínas quiméricas formadas por un antígeno inmunológicamente relevante de un microorganismo patógeno de cerdos y el adyuvante molecular CD154 de cerdos, ii) un adyuvante seleccionado de Ia familia de los di-nucleótidos monofosfatos cíclicos y iii) un excipiente aceptable para Ia inmunización oral. Método de inducir una respuesta inmune contra patógenos que se caracteriza porque se administra por vía oral a un cerdo una formulación inmunogénica que comprende una o varias proteínas quiméricas formadas por i) un antígeno inmunológicamente relevante de un patógeno de cerdos fusionado al adyuvante molecular CD154 de cerdos ii) un adyuvante seleccionado de la familia de los di-nucleótidos monofosfatos cíclicos.<br /> </p>
CU2023000025A 2023-05-18 2023-05-18 Formulación para la inmunización de cerdos por la vía oral CU20230025A7 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CU2023000025A CU20230025A7 (es) 2023-05-18 2023-05-18 Formulación para la inmunización de cerdos por la vía oral
KR1020257041572A KR20260012737A (ko) 2023-05-18 2024-05-10 경구 경로에 의한 돼지 면역용 제제
EP24739076.8A EP4714463A1 (en) 2023-05-18 2024-05-10 Formulation for immunization of pigs by the oral route
CN202480045895.2A CN121463957A (zh) 2023-05-18 2024-05-10 用于通过口服途径对猪进行免疫接种的制剂
PCT/CU2024/050003 WO2024235366A1 (es) 2023-05-18 2024-05-10 Formulación para la inmunización de cerdos por la vía oral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2023000025A CU20230025A7 (es) 2023-05-18 2023-05-18 Formulación para la inmunización de cerdos por la vía oral

Publications (1)

Publication Number Publication Date
CU20230025A7 true CU20230025A7 (es) 2024-12-09

Family

ID=91829963

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000025A CU20230025A7 (es) 2023-05-18 2023-05-18 Formulación para la inmunización de cerdos por la vía oral

Country Status (5)

Country Link
EP (1) EP4714463A1 (es)
KR (1) KR20260012737A (es)
CN (1) CN121463957A (es)
CU (1) CU20230025A7 (es)
WO (1) WO2024235366A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23544A1 (es) * 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica

Also Published As

Publication number Publication date
CN121463957A (zh) 2026-02-03
KR20260012737A (ko) 2026-01-27
WO2024235366A1 (es) 2024-11-21
EP4714463A1 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
Seo et al. Vaccines against gastroenteritis, current progress and challenges
KR102003620B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아 조합 백신
ES2349041T3 (es) Derivados de hidantoina para el tratamiento de trastornos inflamatorios.
JP2015512449A5 (es)
JP2015512448A5 (es)
CA2646574C (en) Vaccine against mycoplasma and prrsv
RU2014140107A (ru) Вакцина mycoplasma hyopneumoniae
RU2009126604A (ru) Вакцина против salmonella
Li et al. Poly (d, l-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic diarrhea virus infection in piglets
US20100316665A1 (en) Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
Rau et al. Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo
WO2021202599A3 (en) Adeno-associated virus based compositions and related methods for inducing humoral immunity
US20130149329A1 (en) Broadly protective shigella vaccine based on type iii secretion apparatus proteins
Poolperm et al. Protection against Pasteurella multocida conferred by an intranasal fowl cholera vaccine in Khaki Campbell ducks
CU20230025A7 (es) Formulación para la inmunización de cerdos por la vía oral
CN101084011A (zh) 猪繁殖与呼吸综合征病毒株及组合物
Zhang et al. Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus
US9913896B2 (en) Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy&#39;s disease)
Collar et al. Progress towards effective vaccines for Chlamydia trachomatis
WO2021011619A1 (en) Senecavirus a virus strains and immunogenic compositions therefrom
BRPI0710550A2 (pt) uso de uma dose imunogênica de material imunogênico de mycoplasma hyopneumoniae e uma dose imunogênica de vìrus de prrs atenuado vivo, kit de vacina, e, método para a vacinação de porcos
Borhani et al. A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies
RU2014147491A (ru) Антигены и антигенные композиции
EA200800917A1 (ru) Адъюванты для вакцин